Oncternal Therapeutics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oncternal Therapeutics stock.
View analyst ratings for Oncternal Therapeutics or view top-rated stocks.

Wall Street analysts have given Oncternal Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncternal Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Oncternal Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 211,300 shares, an increase of 136.6% from the February 28th total of 89,300 shares. Based on an average daily trading volume, of 1,650,000 shares, the days-to-cover ratio is currently 0.1 days.
View Oncternal Therapeutics' Short Interest.

Oncternal Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Oncternal Therapeutics.

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its earnings results on Thursday, March, 11th. The company reported ($0.09) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.09. Oncternal Therapeutics had a negative net margin of 746.10% and a negative trailing twelve-month return on equity of 150.58%.
View Oncternal Therapeutics' earnings history.

5 Wall Street analysts have issued 1-year price objectives for Oncternal Therapeutics' shares. Their forecasts range from $9.00 to $21.00. On average, they anticipate Oncternal Therapeutics' share price to reach $15.20 in the next year. This suggests a possible upside of 127.9% from the stock's current price.
View analysts' price targets for Oncternal Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Oncternal Therapeutics include Phathom Pharmaceuticals (PHAT), Stoke Therapeutics (STOK), Ocular Therapeutix (OCUL), Repare Therapeutics (RPTX), Innoviva (INVA), Northwest Biotherapeutics (NWBO), Praxis Precision Medicines (PRAX), Avid Bioservices (CDMO), Nkarta (NKTX), Dynavax Technologies (DVAX), Protagonist Therapeutics (PTGX), Mersana Therapeutics (MRSN), Y-mAbs Therapeutics (YMAB), Omeros (OMER) and Pliant Therapeutics (PLRX).
View all of ONCT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), The Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX).

Oncternal Therapeutics trades on the NASDAQ under the ticker symbol "ONCT."

Shares of ONCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONCT stock can currently be purchased for approximately $6.67.

Oncternal Therapeutics has a market capitalization of $329.26 million and generates $2.42 million in revenue each year. The company earns $-34,190,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

Oncternal Therapeutics employs 12 workers across the globe.

The official website for Oncternal Therapeutics is www.oncternal.com.

Oncternal Therapeutics is headquartered at 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

Oncternal Therapeutics' mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-434-1113 or via email at [email protected]